Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details Narrative)

v3.19.3.a.u2
Commitments and Contingencies (Details Narrative)
1 Months Ended 12 Months Ended
Oct. 31, 2017
Nov. 30, 2019
USD ($)
Nov. 30, 2017
USD ($)
Nov. 30, 2016
USD ($)
ft²
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Jun. 30, 2019
Monthly lease payments         $ 201,256    
Alachua Facility [Member]              
Period of lease         5 years    
Rental expenses         $ 154,000    
Amendment Alachua Facility [Member]              
Period of lease             5 years
Tampa Facility [Member]              
Period of lease   3 years   36 months      
Rental expenses         64,000    
Area of office space leased | ft²       2,207      
Lease expiry date       Feb. 29, 2020      
Maximum [Member] | Alachua Facility [Member]              
Monthly lease payments         10,851    
Maximum [Member] | Amendment Alachua Facility [Member]              
Monthly lease payments         13,338    
Maximum [Member] | Tampa Facility [Member]              
Monthly lease payments   $ 4,800   $ 4,392      
Minimum [Member] | Alachua Facility [Member]              
Monthly lease payments         9,641    
Minimum [Member] | Amendment Alachua Facility [Member]              
Monthly lease payments         12,870    
Minimum [Member] | Tampa Facility [Member]              
Monthly lease payments   $ 4,524   $ 4,138      
Lantibiotic Exclusive Channel Collaboration [Member]              
Royalty payment of sublicenses percentage 50.00%   25.00%        
Amount required to expended for advancement of lantibiotic program     $ 1,200,000        
Lantibiotic Exclusive Channel Collaboration [Member] | Precigen [Member]              
Cash paid for Commitments         $ 2,250 $ 0  
Lantibiotic Exclusive Channel Collaboration [Member] | Precigen [Member] | Net Sales [Member] | Amendment [Member]              
Royalty payment percentage     10.00%        
Lantibiotic Exclusive Channel Collaboration [Member] | Precigen [Member] | Cost Of Revenue [Member]              
Royalty payment percentage     25.00%        
Lantibiotic Exclusive Channel Collaboration [Member] | Product Profit [Member]              
Reduction in royalty rate percentage     25.00%        
Lantibiotic Exclusive Channel Collaboration [Member] | Net Sales [Member]              
Reduction in royalty rate percentage     10.00%        
Lantibiotic Exclusive Channel Collaboration [Member] | New Drug Application [Member]              
Milestone payment under licensing agreement     $ 25,000,000        
Milestone measurement period     6 months        
Lantibiotic Exclusive Channel Collaboration [Member] | Regulatory Approval Milestone Event [Member]              
Milestone payment under licensing agreement     $ 25,000,000        
Milestone measurement period     6 months        
Lantibiotic Exclusive Channel Collaboration [Member] | New Indication Milestone Event [Member]              
Milestone payment under licensing agreement     $ 5,000,000        
Milestone measurement period     6 months        
Lantibiotic Exclusive Channel Collaboration [Member] | New Product Milestone Event [Member]              
Milestone payment under licensing agreement     $ 5,000,000        
Milestone measurement period     6 months        
Oral Mucositis Exclusive Channel Collaboration [Member]              
Royalty payment of sublicenses percentage 50.00%   25.00%        
Oral Mucositis Exclusive Channel Collaboration [Member] | Maximum [Member]              
Maturity of interest bearing promissory note         12 months    
Oral Mucositis Exclusive Channel Collaboration [Member] | Precigen [Member]              
Cash paid for Commitments         $ 380,900 $ 460,056  
Oral Mucositis Exclusive Channel Collaboration [Member] | Precigen [Member] | Net Sales [Member]              
Royalty payment percentage     12.00%        
Oral Mucositis Exclusive Channel Collaboration [Member] | Precigen [Member] | Cost Of Revenue [Member]              
Royalty payment percentage     25.00%        
Oral Mucositis Exclusive Channel Collaboration [Member] | Regulatory Approval Milestone Event [Member]              
Milestone payment under licensing agreement     $ 27,500,000        
Milestone measurement period     6 months        
Oral Mucositis Exclusive Channel Collaboration [Member] | New Indication Milestone Event [Member]              
Milestone payment under licensing agreement     $ 5,000,000        
Milestone measurement period     6 months        
Oral Mucositis Exclusive Channel Collaboration [Member] | New Product Milestone Event [Member]              
Milestone payment under licensing agreement     $ 5,000,000        
Milestone measurement period     6 months        
Oral Mucositis Exclusive Channel Collaboration [Member] | New Product Application [Member]              
Milestone payment under licensing agreement     $ 27,500,000        
Milestone measurement period     6 months